Open-Label Dose-Escalation Treatment Study of Patients With IPF
Status:
Not yet recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive fibrotic lung disease resulting
in increasing shortness of breath, cough, and low oxygen levels as a result of lung tissue
scarring . The goal of this open-label (no placebo) study is to evaluate the safety and
tolerability of artesunate at three different doses in patients with IPF. The secondary goals
are to explore the blood biomarkers present in IPF patients at the beginning of the study and
to study how those biomarkers change following treatment with artesunate. Participants will
have 7 visits to the study site over 20 weeks which will include physician exams, vital
signs, questionnaires, research and safety blood samples, and taking artesunate capsules by
mouth for 12 weeks.
Artesunate is used world-wide for the treatment of severe malaria but has also been found to
block specific proteins that cause lung scarring and may provide an additional treatment to
slow the fibrotic process in the lung and improve survival and quality of life for patients
with IPF.